Development of DNA vaccines as an anti-hypertensive therapy or for anti-angiogenesis

Bibliography

• Delavallee L, Duvallet E, Semerano L, et al. Anti-cytokine vaccination in autoimmune diseases. Swiss Med Wkly 2010;140:w13108
   Google Scholar
• Dillman RO. Cancer immunotherapy. Cancer Biother Radiopharm 2011;26:1-64
   PubMed Web of Science ®Google Scholar
• Morgan D, Diamond DM, Gottschall PE, et al. A beta peptide vaccination prevents memory loss in an animal model of alzheimer’s disease. Nature 2000;408:982-5
   PubMed Web of Science ®Google Scholar
• Schenk D. Amyloid-beta immunotherapy for alzheimer’s disease: the end of the beginning. Nat Rev Neurosci 2002;3:824-8
   PubMed Web of Science ®Google Scholar
• Tissot AC, Maurer P, Nussberger J, et al. Effect of immunisation against angiotensin ii with cyt006-angqb on ambulatory blood pressure: a double-blind, randomised, placebo-controlled phase iia study. Lancet 2008;371:821-7
   PubMed Web of Science ®Google Scholar
• Hagström B, Mattson B, Rost IM, et al. What happened to the prescriptions? A single, short, standardized telephone call may increase compliance. Fam Pract 2004;21:46-50
   PubMed Web of Science ®Google Scholar
• Orgogozo JM, Gilman S, Dartigues JF, et al. Subacute meningoencephalitis in a subset of patients with ad after abeta42 immunization. Neurology 2003;61:46-54
   PubMed Web of Science ®Google Scholar
• Ferrer I, Boada Rovira M, Sanchez Guerra ML, et al. Neuropathology and pathogenesis of encephalitis following amyloid-beta immunization in alzheimer’s disease. Brain Pathol 2004;14:11-20
   PubMed Web of Science ®Google Scholar
• Nicoll JA, Wilkinson D, Holmes C, et al. Neuropathology of human alzheimer disease after immunization with amyloid-beta peptide: a case report. Nat Med 2003;9:448-52
   PubMed Web of Science ®Google Scholar
• Gardiner SM, Auton TR, Downham MR, et al. Active immunization with angiotensin I peptide analogue vaccines selectively reduces the pressor effects of exogenous angiotensin I in conscious rats. Br J Pharmacol 2000;129:1178-82
   Web of Science ®Google Scholar
• Brown MJ, Coltart J, Gunewardena K, et al. Randomized double-blind placebo-controlled study of an angiotensin immunotherapeutic vaccine (pmd3117) in hypertensive subjects. Clin Sci (Lond) 2004;107:167-73
   PubMed Web of Science ®Google Scholar
• Ambuhl PM, Tissot AC, Fulurija A, et al. A vaccine for hypertension based on virus-like particles: preclinical efficacy and phase i safety and immunogenicity. J Hypertens 2007;25:63-72
   PubMed Web of Science ®Google Scholar
• Wakerlin GE. Antibodies to renin as proof of the pathogenesis of sustained renal hypertension. Circulation 1958;17:653-7
   PubMed Web of Science ®Google Scholar
• Katz JI, Skom JH, Wakerlin GE. Pathogenesis of spontaneous and pyelonephritic hypertension in the dog. Circ Res 1957;5:137-43
   PubMed Web of Science ®Google Scholar
• Helmer OM. Studies on renin antibodies. Circulation 1958;17:648-52
   PubMed Web of Science ®Google Scholar
• Frank MH. Renin in experimental renal hypertension in monkeys. Circ Res 1963;12:241-55
   PubMed Web of Science ®Google Scholar
• Deodhar SD, Haas E, Goldblatt H. Production of antirenin to homologous renin and its effect of experimental renal hypertension. J Exp Med 1964;119:425-32
   PubMed Web of Science ®Google Scholar
• Skeggs LT, Kahn JR, Levine M, et al. Chronic one-kidney hypertension in rabbits. I. Treatment with kidney extracts. Circ Res 1975;37:715-24
   PubMed Web of Science ®Google Scholar
• Michel JB, Guettier C, Philippe M, et al. Active immunization against renin in normotensive marmoset. Proc Natl Acad Sci USA 1987;84:4346-50
   PubMed Web of Science ®Google Scholar
• Michel JB, Sayah S, Guettier C, et al. Physiological and immunopathological consequences of active immunization of spontaneously hypertensive and normotensive rats against murine renin. Circulation 1990;81:1899-910
   PubMed Web of Science ®Google Scholar
• Downham MR, Auton TR, Rosul A, et al. Evaluation of two carrier protein-angiotensin i conjugate vaccines to assess their future potential to control high blood pressure (hypertension) in man. Br J Clin Pharmacol 2003;56:505-12
   PubMed Web of Science ®Google Scholar
• Unger T, Paulis L, Sica DA. Therapeutic perspectives in hypertension: novel means for renin-angiotensin-aldosterone system modulation and emerging device-based approaches. Eur Heart J 2011;32:2739-47
   PubMed Web of Science ®Google Scholar
• Nakagami F, Koriyama H, Nakagami H, et al. Decrease in blood pressure and regression of cardiovascular complications by angiotensin II vaccine in mice. PLoS One 2013;8:e60493
   PubMed Web of Science ®Google Scholar
• Valdor R, Macian F. Induction and stability of the anergic phenotype in T cells. Semin Immunol 2013;25:313-20
   PubMed Web of Science ®Google Scholar
• Agadjanyan MG, Ghochikyan A, Petrushina I, et al. Prototype alzheimer’s disease vaccine using the immunodominant b cell epitope from beta-amyloid and promiscuous t cell epitope pan hla dr-binding peptide. J Immunol 2005;174:1580-6
   PubMed Web of Science ®Google Scholar
• Lechner F, Jegerlehner A, Tissot AC, et al. Virus-like particles as a modular system for novel vaccines. Intervirology 2002;45:212-17
   PubMed Web of Science ®Google Scholar
• Pumpens P, Grens E. HBV core particles as a carrier for B cell/T cell epitopes. Intervirology 2001;44:98-114
   PubMed Web of Science ®Google Scholar
• Plescia OJ. The role of the carrier in antibody formation. Curr Top Microbiol Immunol 1969;50:78-106
   PubMedGoogle Scholar
• Verdier F. Non-clinical vaccine safety assessment. Toxicology 2002;174:37-43
   PubMed Web of Science ®Google Scholar
• Paul S, Kenny AB, Hitzig WH. Immune response to keyhole-limpet hemocyanin in the human. Int Arch Allergy Appl Immunol 1974;47:155-60
   PubMedGoogle Scholar
• Lindblad EB. Aluminium compounds for use in vaccines. Immunol Cell Biol 2004;82:497-505
   PubMed Web of Science ®Google Scholar
• Batchelor TT, Sorensen AG, di Tomaso E, et al. AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell 2007;11:83-95
   PubMed Web of Science ®Google Scholar
• Kane RC, Farrell AT, Saber H, et al. Sorafenib for the treatment of advanced renal cell carcinoma. Clin Cancer Res 2006;12:7271-8
   PubMed Web of Science ®Google Scholar
• Teng LS, Jin KT, He KF, et al. Clinical applications of VEGF-trap (aflibercept) in cancer treatment. J Chin Med Assoc 2010;73:449-56
   PubMed Web of Science ®Google Scholar
• Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350:2335-42
   PubMed Web of Science ®Google Scholar
• Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin Alone or with Bevacizumab for Non-small-Cell Lung Cancer. N Engl J Med 2006;355:2542-50
   PubMed Web of Science ®Google Scholar
• Miller K, Wang M, Gralow J, et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 2007;357:2666-76
   PubMed Web of Science ®Google Scholar
• Friedman HS, Prados MD, Wen PY, et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol 2009;27:4733-40
   PubMed Web of Science ®Google Scholar
• Giantonio BJ, Catalano PJ, Meropol NJ, et al. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol 2007;25:1539-44
   PubMed Web of Science ®Google Scholar
• Holash J, Davis S, Papadopoulos N, et al. VEGF-Trap: a VEGF blocker with potent antitumor effects. Proc Natl Acad Sci USA 2002;99:11393-8
   PubMed Web of Science ®Google Scholar
• Lockhart AC, Rothenberg ML, Dupont J, et al. Phase I Study of intravenous vascular endothelial growth factor trap, aflibercept, in patients with advanced solid tumors. J Clin Oncol 2010;28:207-14
   PubMed Web of Science ®Google Scholar
• Gomez-Manzano C, Holash J, Fueyo J, et al. VEGF Trap induces antiglioma effect at different stages of disease. Neuro-oncol 2008;10:940-5
   PubMed Web of Science ®Google Scholar
• Kyutoku M, Nakagami H, Koriyama H, et al. Development of novel DNA vaccine for VEGF in murine cancer model. Sci Rep 2013;3:3380
   PubMed Web of Science ®Google Scholar
• Strassmann G, Jacob CO, Evans R, et al. Mechanisms of experimental cancer cachexia. Interaction between mononuclear phagocytes and colon-26 carcinoma and its relevance to IL-6-mediated cancer cachexia. J Immunol 1992;148:3674-8
   PubMed Web of Science ®Google Scholar
• Pedersen AE, Buus S, Claesson MH. Treatment of transplanted CT26 tumour with dendritic cell vaccine in combination with blockade of vascular endothelial growth factor receptor 2 and CTLA-4. Cancer Lett 2006;235:229-38
   PubMed Web of Science ®Google Scholar
• Nakagami H, Koriyama H, Morishita R. Therapeutic vaccines for hypertension and dyslipidemia. Int Heart J 2014;55:96-100
   PubMed Web of Science ®Google Scholar